These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24486595)

  • 21. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
    J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.
    Merchionne F; Quintana G; Gaudio F; Minoia C; Specchia G; Guarini A; Quarta G; Pavone V; Melpignano A
    Leuk Res; 2014 Dec; 38(12):1446-50. PubMed ID: 25455656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
    Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
    Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survivin and YM155: how faithful is the liaison?
    Rauch A; Hennig D; Schäfer C; Wirth M; Marx C; Heinzel T; Schneider G; Krämer OH
    Biochim Biophys Acta; 2014 Apr; 1845(2):202-20. PubMed ID: 24440709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice.
    Zhao N; Mao Y; Han G; Ju Q; Zhou L; Liu F; Xu Y; Zhao X
    Oncotarget; 2015 Jul; 6(21):18445-59. PubMed ID: 26090615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
    Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
    Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
    Gopal AK; Tarantolo SR; Bellam N; Green DJ; Griffin M; Feldman T; Mato AR; Eisenfeld AJ; Stromatt SC; Goy A
    Invest New Drugs; 2014 Dec; 32(6):1213-25. PubMed ID: 24927856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
    Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
    Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
    Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
    Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
    Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.
    Qin Q; Cheng H; Lu J; Zhan L; Zheng J; Cai J; Yang X; Xu L; Zhu H; Zhang C; Liu J; Ma J; Zhang X; Dai S; Sun X
    J Hematol Oncol; 2014 Aug; 7():62. PubMed ID: 25139395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
    Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
    BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
    Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
    Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
    Huang J; Lyu H; Wang J; Liu B
    Cancer Lett; 2015 Oct; 366(2):160-72. PubMed ID: 26123662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
    Minematsu T; Iwai M; Sugimoto K; Shirai N; Nakahara T; Usui T; Kamimura H
    Drug Metab Dispos; 2009 Mar; 37(3):619-28. PubMed ID: 19056913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
    Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
    Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.